Kliniken Essen-Mitte

Running trials

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Source

• Recruiting

  A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Source

• Recruiting

  A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

  NCT07022483· Phase 3· Source

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· Source

• Active, not recruiting

  Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

  NCT06430866· Phase 3· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  NCT06312176· Phase 3· Source

• Recruiting

  LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus

  NCT05714930· Source

• Active, not recruiting

  A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

  NCT04975308· Phase 3· Source

• Active, not recruiting

  Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

  NCT04595565· Phase 3· Source

• Active, not recruiting

  Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

  NCT03443856· Phase 2· Source

• Active, not recruiting

  Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

  NCT03821935· Phase 1· Source

• Active, not recruiting

  International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer

  NCT03386734· Source

• Recruiting

  Endometrial Cancer Lymphadenectomy Trial

  NCT03438474· Source

• Active, not recruiting

  Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

  NCT02947685· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Endometrial cancer3 recruiting
• Metastatic breast cancer2 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Ovarian cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)

  NCT05546905· Source

• Completed

  MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab

  NCT04554836· Phase 2· Source

• Completed

  Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

  NCT04227522· Phase 3· Source

• Terminated

  Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)

  NCT03891576· Phase 2· Source

• Completed

  Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

  NCT03598270· Phase 3· Source

• Completed

  Atezolizumab Trial in Endometrial Cancer - AtTEnd

  NCT03603184· Phase 3· Source

• Completed

  Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

  NCT03530267· Phase 2· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· Source

• Completed

  Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

  NCT03310957· Phase 1/2· Source

• Completed

  A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

  NCT03412773· Phase 3· Source

• Completed

  Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

  NCT03081143· Phase 2/3· Source

• Completed

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· Phase 3· Source

• Completed

  Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT02205047· Phase 2· Source

• Recruiting

  Praegnant Breast Cancer: Early/Advanced/Metastatic

  NCT02338167· Source

• Completed

  Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

  NCT01658930· Source

Trial sites

• Kliniken Essen-Mitte12 trials
• Kliniken Essen-Mitte - 22060 trials
• Kliniken Essen Mitte, Essen1 trial
• Kliniken Essen-Mitte; Evangelische Huyssens-Stiftung4 trials
• Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung /ID# 2695871 trial
• Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung-Klinike für Senologie/ Brustzentrum (Site 12000 trials
• Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung-Klinike für Senologie/ Brustzentrum (Site 1300)1 trial
• Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung Loc. 12 trials
• Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung (Site 0611)0 trials
• Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung (Site 1001)0 trials
• Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung (Site 1104)0 trials
• Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung (Site 1400)0 trials
• Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung (Site 2104)0 trials
• Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung (Site 2105)0 trials
• Kliniken Essen-Mitte - Evang. Huyssens-Stiftung6 trials
• Kliniken Essen Mitte, Evang. Huyssens-Stiftung, Internistische Onkologie und Hmatologie mit integire1 trial
• Kliniken Essen-Mitte, Evang. Huyssens-Stiftung/Knappschaft GmbH2 trials
• Kliniken Essen Mitte, Evang. Huyssens Stiftung/Knappschaft GmbH, Gynäkologische Onkologie1 trial
• Kliniken Essen-Mitte - Gynaekologie und Gynaekologische Onkologie0 trials
• Kliniken Essen-Mitte/Huyssens-Stift0 trials
• Kliniken Essen Mitte (Site 1012)0 trials
• Kliniken Essen Mitte (Site 1517)0 trials
• Kliniken Essen Mitte (Site 1567)0 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Ovarian cancer86 works · 8 trials